Table 1.

Characteristics of patients starting ART at the CePReF HIV care center, Abidjan, Côte d’Ivoire, 2005–2008

	Dead, transferred out or LTFU before Month-6 (n=438)	Still in care at Month-6
		Enhanced follow-up (n= 637)	Routine follow-up (n=999)	p-value
Female, n (%)	289 (66)	475 (75)	741 (74)	0.88
Age in years, median (IQR)	36 (30–43)	37 (31–43)	36 (30–43)	0.50
Living outside the district, n (%)	153 (35)	215 (34)	360 (36)	0.32
Pre-ART Body Mass Index (kg/m2), median (IQR)	18.0 (16.0–20.2)	19.8 (17.8–22.1)	20.1 (17.9–22.5)	0.25
Pre-ART CD4 count (/mm3), median (IQR)	97 (25–194)	148 (71–226)	147 (58–233 )	0.69
First-line ART regimen, n (%)				0.04
2 NRTIs + 1 NNRTI	417 (95)	619 (97)	952 (95)
2 NRTIs + 1 PI	19 (4)	16 (3)	42 (4)
3 NRTIs	1 (0)	0 (0)	5 (1)
M0-M6 Medication Possession Ratio, median (IQR)	74 (33–100)	95 (83–99)	96 (81–101)	0.09

ART: antiretroviral therapy; IQR : inter-quartile range ; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor. LTFU: lost to follow-up.

p-value is for comparison between routine and enhanced follow-up between 6 and 18 months among patients still in care at month-6.

M0-M6 Medication Possession Ratio: number of daily doses of antiretroviraldrug provided between ART start and month-6, divided by total number of follow-up days between ART start and month-6